In:
Cancer, Wiley, Vol. 128, No. 24 ( 2022-12-15), p. 4213-4222
Abstract:
Acute myeloid leukemia (AML) with hyperleukocytosis is enriched for molecular subtypes that negatively affect the prognosis, including a high percentage of patients presenting with co‐occurring mutations in signaling and epigenetic modifiers such as FLT3 internal tandem duplication and TET2 mutations. Despite these unique molecular features, clinical risk factors, including high white blood counts, hemoglobin levels, and lactate dehydrogenase levels at the baseline, remain the predictors for overall survival and relapse‐free survival in hyperleukocytotic cytogenetically normal AML.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v128.24
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink